Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

Anabolic bone therapies in 2014

New bone-forming treatments for osteoporosis

Nature Reviews Endocrinology volume 11, pages 69–70 (2015)Cite this article

Subjects

In 2014, two phase II clinical studies reported rapid, impressive increases in BMD in women with low bone mass who were treated with sclerostin inhibitors for 1 year. The antifracture efficacy and tolerability of these new, bone-building therapies are currently being investigated in phase III clinical trials.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Bone turnover in response to anabolic bone therapies.

References

  1. Tsai, J. N. et al. Teriparatide and denosumab, alone or combined in women with postmenopausal osteoporosis: the DATA study randomized trial. Lancet 382, 50–56 (2013).

    Article  CAS  Google Scholar 

  2. Leder, B. Z. et al. Two years of denosumab and teriparatide administration in postmenopausal women with osteoporosis (the DATA extension study): a randomized controlled trial. J. Clin. Endocrinol. Metab. 99, 1694–1700 (2014).

    Article  CAS  Google Scholar 

  3. Ke, H. Z., Richards, W. G., Li, X. & Ominsky, M. S. Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases. Endocr. Rev. 33, 747–783 (2012).

    Article  CAS  Google Scholar 

  4. Moester, M. J., Papapoulos, S. E., Lowik, C. W. & van Bezooijen, R. L. Slerostin: current knowledge and future perspectives. Calcif. Tissue Int. 87, 99–107 (2010).

    Article  CAS  Google Scholar 

  5. Li, X. et al. Sclerostin antibody treatment increases bone formation, bone mass and bone strength in a rat model of postmenopausal osteoporosis. J. Bone Miner. Res. 24, 578–588 (2009).

    Article  CAS  Google Scholar 

  6. Ominsky, M. S. et al. Two doses of sclerostin antibody in cynomologous monkeys increase bone formation, bone mineral density and bone stength. J. Bone Miner. Res. 25, 948–959 (2010).

    Article  CAS  Google Scholar 

  7. Padhi, D., Jang, G., Struch, B., Fang, L. & Posrar, E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J. Bone Miner. Res. 26, 19–26 (2011).

    Article  CAS  Google Scholar 

  8. Recker, R. et al. A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density. J. Bone Miner. Res. http://dx.doi.org/10.1002/jbmr.2351.

  9. McClung, M. R. et al. Romosozumab in postmenopausal women with low bone mineral density. N. Engl. J. Med. 370, 412–420 (2014).

    Article  CAS  Google Scholar 

  10. Ominsky, M. S., Niu, Q.-T., Li, C., Li, X. & Ke, H. Z. Tissue-level mechanisms responsible for the increase in bone formation and bone volume by sclerostin antibody. J. Bone Miner. Res. 29, 1424–1430 (2014).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The author's studies on sclerostin are supported by and carried out within the FP7 programme TALOS, which is funded by the European Commission (Grant Number: TALOS:Health-F2-2008-201,099).

Author information

Authors and Affiliations

  1. Center for Bone Quality, Leiden University Medical Center, Albinusdreef 2, Leiden, 2333 ZA, Netherlands

    Socrates E. Papapoulos

Authors
  1. Socrates E. Papapoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Socrates E. Papapoulos.

Ethics declarations

Competing interests

The author has received consulting fees and speaker honoraria from Amgen and UCB.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Papapoulos, S. New bone-forming treatments for osteoporosis. Nat Rev Endocrinol 11, 69–70 (2015). https://doi.org/10.1038/nrendo.2014.214

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrendo.2014.214

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing